Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment

被引:9
作者
Gouw, S. C. [1 ,2 ]
Ter Avest, P. C. [1 ]
Van Helden, P. M. [3 ,4 ]
Voorberg, J. [3 ,4 ]
Van Den Berg, H. M. [1 ,5 ]
机构
[1] Univ Med Ctr Utrecht, Creveldklin, Dept Pediat, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat, NL-3508 GA Utrecht, Netherlands
[3] AMC Sanquin Res, Dept Plasma Prot, Van Creveld Lab, Amsterdam, Netherlands
[4] AMC Sanquin Res, Landsteiner Lab, Amsterdam, Netherlands
[5] Univ Med Ctr Utrecht, Dept Lab Med, Utrecht, Netherlands
关键词
factor VIII inhibitors; IgG subclasses; immune tolerance induction; intensity of treatment; rituximab; IMMUNE TOLERANCE INDUCTION; PREVIOUSLY UNTREATED PATIENTS; FACTOR-VIII INHIBITORS; IGG SUBCLASSES; RISK-FACTORS; POLYMORPHISMS; CHILDREN; GENE;
D O I
10.1111/j.1365-2516.2009.01998.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Both genetic factors and environmental factors are suggested to play a role in the aetiology of inhibitor development in patients with severe haemophilia A. Monozygotic twins are ideal candidates to study the influence of environmental factors. We describe a pair of 3-year-old monozygotic twin brothers with severe haemophilia A. Prenatal diagnosis confirmed the presence of an intron 22 inversion. Other patient-related factors such as birth weight, vaccinations and the duration of breastfeeding were similar. At the age of 7 months, one boy suffered from a spontaneous subdural haematoma, which needed complete correction of haemostasis with continuous infusion of a third-generation recombinant factor VIII. A persistent high-titre inhibitor with severe clinical symptoms developed, that could only be eradicated with high-dose immune tolerance induction (ITI) for 36 months in combination with rituximab therapy. His twin brother first received treatment at 9 months of age with the same FVIII product. After treatment on nine exposure days, he developed a low-titre inhibitor at the age of 14.5 months. Unlike his brother, he was tolerized without difficulties with low-dose ITI within 2 months. The discordant antibody responses were underlined by dissimilar IgG1 and IgG4 levels in their plasma. The discordant immune response to FVIII in this pair of monozygotic twin brothers seemed to be related to intensity of treatment and severity of bleeds. This confirms that these environmental factors play an additional role in the development of inhibitors.
引用
收藏
页码:712 / 717
页数:6
相关论文
共 28 条
  • [1] Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A
    Astermark, J.
    Wang, X.
    Oldenburg, J.
    Berntorp, E.
    Lefvert, A. -K.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (02) : 263 - 265
  • [2] Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A
    Astermark, J
    Oldenburg, J
    Pavlova, A
    Berntorp, E
    Lefvert, AK
    [J]. BLOOD, 2006, 107 (08) : 3167 - 3172
  • [3] The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development
    Astermark, J
    Berntorp, E
    White, GC
    Kroner, BL
    [J]. HAEMOPHILIA, 2001, 7 (03) : 267 - 272
  • [4] Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A
    Astermark, Jan
    Oldenburg, Johannes
    Carlson, Joyce
    Pavlova, Anna
    Kavakli, Kaan
    Berntorp, Erik
    Lefvert, Ann-Kari
    [J]. BLOOD, 2006, 108 (12) : 3739 - 3745
  • [5] Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience
    Carcao, M
    St Louis, J
    Poon, MC
    Grunebaum, E
    Lacroix, S
    Stain, AM
    Blanchette, VS
    Rivard, GE
    [J]. HAEMOPHILIA, 2006, 12 (01) : 7 - 18
  • [6] Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A
    Chalmers, E. A.
    Brown, S. A.
    Keeling, D.
    Liesner, R.
    Richards, M.
    Stirling, D.
    Thomas, A.
    Vidler, V.
    Williams, M. D.
    Young, D.
    [J]. HAEMOPHILIA, 2007, 13 (02) : 149 - 155
  • [7] The international immune tolerance study: a multicenter prospective randomized trial in progress
    DiMichele, D. M.
    Hay, C. R. M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (10) : 2271 - 2273
  • [8] DiMichele DM, 2002, THROMB HAEMOSTASIS, V87, P52
  • [9] Role of von Willebrand factor in immune tolerance induction
    Ettingshausen, CE
    Kreuz, W
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2005, 16 : S27 - S31
  • [10] FROMMEL D, 1979, SCAND J HAEMATOL, V23, P64